Search This Blog

Wednesday, January 31, 2024

Revelation: Positive Data from Preclinical Ischemia Reperfusion Acute Kidney Injury Model -

 Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that new preclinical data on the potential therapeutic benefit of Gemini for the prevention of acute kidney injury (AKI) will be presented at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) taking place in San Diego (March 12-15, 2024). Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD®), a toll-like receptor 4 (TLR4) agonist, in development for prevention of AKI and hospital acquired infection.

Title:

Intravenous Gemini for Prevention of Acute Kidney Injury

Presenter:

Robin Marsden, Senior Vice President of Biology, Revelation Biosciences

Date/Time:

Tuesday, March 12, 2024 5:30 p.m. -7:30 p.m. Pacific Time



https://www.businesswire.com/news/home/20240130907237/en/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.